FDA Cleared vs FDA Approved: What the Difference Means for Medical Devices

2026-10-02 · Caduvo Team

Using 'FDA approved' for a 510(k)-cleared medical device is legally actionable misbranding. Learn the exact statutory differences between cleared, approved, granted, and listed.

Medical device pitch decks, press releases, and commercial websites routinely state that a new product is "FDA approved." In most cases, that claim is factually inaccurate and creates regulatory exposure. If your device reached the market through a 510(k) submission, it is not FDA approved—it is FDA cleared. If it entered through the De Novo pathway, marketing authorization was granted. Only Class III devices evaluated through Premarket Approval (PMA) applications are legally "FDA approved."

When comparing FDA cleared vs approved medical devices, the distinction is not semantics; it reflects fundamentally different statutory standards, clinical evidence bars, and commercial claims boundaries. Understanding the nuances of FDA cleared vs FDA approved pathways determines what data you must collect, how you talk to investors, and what language your sales team can print on packaging. The agency clears Class II devices via the 510(k) pathway when a manufacturer demonstrates substantial equivalence to a legally marketed predicate. The FDA approves Class III devices through Premarket Approval (PMA) applications only after reviewing valid scientific evidence—typically prospective human clinical trials—demonstrating reasonable assurance of safety and effectiveness. Class I devices are generally exempt from premarket review and simply registered and listed, while novel moderate-risk devices are granted marketing authorization under the De Novo process.

Calling a 510(k)-cleared product "FDA approved" misbrands the device under federal law. It can prompt regulatory warning letters, delay hospital procurement, and derail investor due diligence.

The Four Regulatory Tiers and Their Evidentiary Bars

The Medical Device Amendments of 1976 established three statutory risk classes for medical devices based on the degree of control necessary to assure safety and effectiveness. Each classification corresponds to a specific regulatory status and a distinct standard of proof.

1. 510(k) Premarket Notification: "FDA Cleared"

Class II devices account for approximately 43% of all medical devices in the United States, spanning products from powered wheelchairs to some pregnancy test kits. Under Section 510(k) of the Federal Food, Drug, and Cosmetic (FD&C) Act, manufacturers must submit a premarket notification at least 90 days before marketing a device commercially.

A 510(k) clearance does not mean the FDA evaluated your device from scratch to determine whether it is independently safe and effective. Instead, clearance certifies that the device is "substantially equivalent" to an already legally marketed predicate device. To establish substantial equivalence, the sponsor must show that the device has the same intended use and either identical technological characteristics or different technological characteristics that do not raise new questions of safety and effectiveness.

Most 510(k) submissions rely on non-clinical performance testing. Human clinical studies conducted under an Investigational Device Exemption (IDE) are required in rare situations for only a small percentage of 510(k) submissions. Since October 1, 2023, all non-exempt 510(k) filings must use the electronic Submission Template And Resource (eSTAR) format through the CDRH Customer Collaboration Portal.

2. Premarket Approval (PMA): "FDA Approved"

Class III devices represent roughly 10% of medical devices. These are devices that sustain or support life, are implanted, or present a potential, unreasonable risk of illness or injury—such as pacemakers and breast implants.

Premarket Approval (PMA) under Section 515 of the FD&C Act and 21 CFR Part 814 is the agency's most stringent marketing application. Approval is not based on equivalence. The FDA independently evaluates whether the application contains sufficient "valid scientific evidence" from human clinical trials to provide reasonable assurance that the device is safe and effective for its intended use.

An approved PMA functions like a private license granted specifically to the applicant for marketing a particular medical device. A competitor cannot cite an approved PMA as a predicate for a simple 510(k); they must submit their own application or qualify for another statutory pathway.

3. De Novo Classification: "Granted"

Added by the Food and Drug Administration Modernization Act of 1997, the De Novo pathway (Evaluation of Automatic Class III Designation) provides an alternate route to classify novel devices of low to moderate risk.

Without the De Novo process, any novel device without a predicate automatically defaulted into Class III, requiring a costly PMA regardless of its actual risk. Through a De Novo request, the sponsor petitions the agency to evaluate the device. When the FDA determines that general controls (or general plus special controls) provide reasonable assurance of safety and effectiveness, the agency grants marketing authorization. Devices classified through De Novo may be marketed and used as predicates for future 510(k) submissions.

4. Class I Exempt: "Registered and Listed"

Class I devices account for roughly 47% of medical devices, and about 95% of these are exempt from the regulatory premarket notification process. Examples include manual stethoscopes, mercury thermometers, and bedpans.

Exempt device makers do not receive clearance or approval. Instead, facilities that manufacture or distribute these devices must register their establishment annually and list their generic product with the FDA. No formal clearance or approval letter is issued.

Why "FDA Approved" on a 510(k) Device Triggers Regulatory Risk

The gap between "cleared" and "approved" is not a grammatical technicality. Using the term "FDA approved" to market a 510(k)-cleared device misbrands the product under the Federal Food, Drug, and Cosmetic Act.

The agency's enforcement position is clear: claiming a 510(k) device is "approved" falsely implies that the FDA independently reviewed clinical trials to confirm safety and effectiveness, rather than verifying substantial equivalence to a predecessor.

Similarly, displaying mock certificates or claiming to be "FDA certified" creates legal exposure. The FDA does not issue registration certificates to medical device facilities, nor does it certify registration data. Third-party vendors frequently issue decorative certificates with the FDA logo to businesses that complete their registration. Firms that display these certificates alongside information about and photos of a device to imply review or approval misbrand the device under federal law.

There is also a significant volume disparity across pathways. Of the device decisions tracked within Caduvo's regulatory intelligence database, 510(k) clearances outnumber original PMA approvals by more than ten to one. Because the vast majority of commercial devices enter the market through substantial equivalence, the temptation to upgrade promotional copy to "approved" is common—and monitored by FDA compliance officers and competitor counsel.

What Payers and Value Analysis Committees Infer from Your Pathway

Your regulatory pathway sends a direct signal to insurance medical directors and hospital procurement committees. Understanding how they interpret that signal is central to your medical device market access planning.

When evaluating a PMA-approved device, review committees recognize that the FDA reviewed valid scientific evidence collected from human clinical trials showing safety and effectiveness. The clinical data required for a PMA often forms the basis of published peer-reviewed literature that payers examine during medical policy development.

Conversely, when evaluating a 510(k)-cleared device, reviewers understand that the agency assessed substantial equivalence rather than requiring independent clinical trials from scratch. Because only a small percentage of 510(k) submissions contain clinical data, payers and hospital committees often ask for supplemental clinical evidence to confirm clinical utility before establishing coverage or purchasing agreements.

Hospital Value Analysis Committees operate under similar scrutiny. A hospital procurement team evaluating a new surgical device will verify whether promotional claims align with cleared indications. If marketing literature cites "FDA approval" for a Class II device, hospital risk managers frequently flag the discrepancy, pausing evaluations until regulatory documentation is clarified.

Rules for Commercial Labeling, Pitch Decks, and Websites

To ensure your promotional materials and public statements remain defensible during regulatory reviews, investor diligence, and commercial distribution, align internal communications with these practical guardrails:

Use statutory terms accurately:

For a 510(k): State that the device is "510(k) cleared" or "cleared by the FDA for commercial distribution."
For a De Novo submission: State that the device was "granted marketing authorization under the De Novo pathway."
For a PMA: State that the device is "FDA approved."
For Class I exempt products: State that the facility is registered and the product is listed with the FDA. Never state that the product itself is cleared or approved.

Never claim "FDA Certified": The FDA does not issue device registration certificates or certify registration information. Remove all references to certification from packaging, sell sheets, and website footers.

Do not use certificates displaying the FDA logo to imply review: Displaying decorative certificates featuring the FDA logo alongside product information to imply FDA review or approval violates the FD&C Act and misbrands the product.

Audit investor materials for regulatory precision: Investors conducting technical diligence search CDRH databases directly. Claiming "FDA approval" in a pitch deck for a product cleared through a 510(k) signals either regulatory unsophistication or deliberate misrepresentation.

Differentiate facility registration from product authorization: Mere registration of an establishment or listing of a device does not denote approval, clearance, or authorization of that facility or its products, nor does it mean the product may be legally marketed.

Actionable Guardrails for Commercial Teams

Marketing copy and regulatory filings cannot exist in separate silos. Before any commercial campaign, website launch, or investor deck distribution, implement a structured verification routine:

Cross-check every public product claim against your exact FDA clearance order, De Novo grant summary, or PMA approval order.
Inspect websites, distributor portals, and packaging to remove "FDA approved" from all Class I and Class II promotional lines.
Train sales representatives that establishment registration is a mandatory administrative requirement, not an agency endorsement.
Prepare market access dossiers that supplement 510(k) clearances with clinical outcome data to satisfy the evidentiary expectations of commercial payers and hospital committees.